Modular Medical, Inc. (MODD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Modular Medical, Inc. on November 21, 2024, with a report date of November 21, 2024. The filing details the entry into a material definitive agreement for a firm commitment underwritten offering of common stock. The offering closed on November 25, 2024.
Key Financial Metrics and Transaction Details
- Shares Issued: 5,450,573 shares of Common Stock.
- Public Offering Price: $1.50 per share.
- Gross Proceeds: Approximately $8.2 million (before underwriting discounts, commissions, and offering expenses).
- Underwriter Warrants: 381,540 warrants issued to the underwriter (7% of shares sold).
- Warrant Terms: Exercise price of $1.875 per share (125% of offering price); exercisable starting May 21, 2025; expiring November 25, 2029.
Material Changes and Agreements
The primary material change is the capital raise via the underwritten offering. The Company entered into an Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC. This transaction significantly increases the Company's cash position, though net proceeds are reduced by underwriting costs not specified in this text.
Restrictions, Risks, and Management Commentary
- Lock-Up Agreements: Directors and executive officers are subject to a 60-day lock-up period following the closing date, prohibiting the sale or transfer of securities without underwriter consent.
- Issuance Restrictions: The Company is prohibited from issuing Common Stock or equivalents during the 60-day lock-up period (with certain exempt issuances) and from engaging in variable rate transactions for one year from the closing date.
- Legal Opinion: A legal opinion regarding the shares was provided by Lucosky Brookman, LLP.
Investor Verification Checklist
- Verify the exact net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds ($8.2 million) are stated.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific details on underwriting fees and indemnification.
- Confirm the dilution impact of the 381,540 underwriter warrants on existing shareholders.
- Check subsequent filings for the use of proceeds and any changes to the Company's liquidity position post-closing.